Despite intense research, therapy for NAFLD always remains unmet medical attention. Interventions aim at different aspects of presumed risks for hepatic steatosis (obesity, insulin resistance, and hypertension). Lifestyle modifications are proven to be useful not only in the prevention and control of the disease but also in the reduction of associated comorbidities, with promising results. Long-term adherence and sustained improvement are not, however, documented in most subjects. Targeting therapies aiming at mitigating specific pathways of NAFLD along with cellular and molecular events at various stages of the pathogenesis are attempted with varying degree of success. Many longitudinal studies have shown that the presence and severity (stage)of fibrosis on liver histology correlates with increased risk of all-cause as well as liver-related mortality in patients with NAFLD. Specific treatments aimed at this aspect are also evaluated. This review summarizes the current treatment options in the management of NASH and therapies which are being actively evaluated (including phase II/III clinical trials) with promising data.